Fulgent Genetics Stock

Fulgent Genetics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Fulgent Genetics (FLGT) as of Aug 1, 2026 is 205.26 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 45.09 % — a change of 355.28% (higher).

FCF Conversion

205.26 %

YoY

355.28%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Fulgent Genetics is 2026 205.26 % . FCF Conversion Rate (FCF/EBITDA) of Fulgent Genetics was 2025 45.09 % . It decreases by 355.28% higher compared to the previous year.
Access this data via the Eulerpool API

Fulgent Genetics Stock analysis

What does Fulgent Genetics do? Fulgent Genetics Inc. is a US company founded in 2011 by Jianxing (Justin) Liu and Ming Hsieh. The company has undergone remarkable development and is now active in the field of genomics and genetics. Fulgent Genetics' business model is based on the development and distribution of solutions for the diagnosis of genetic diseases. The company offers a variety of products and services that enable doctors, clinics, and laboratories to make effective diagnoses based on genetics. One of Fulgent Genetics' main divisions is the Clinical Diagnostics department, which offers a wide range of diagnostic products that allow for both molecular diagnoses and the creation of clinical profiles for patients. This enables doctors and clinics to quickly and accurately detect and treat specific diseases. Another important division of Fulgent Genetics is the Research department, which focuses on the discovery and development of new technologies and testing procedures. These technologies and procedures are of great interest to the scientific community and are used in research or clinical studies. Fulgent Genetics also offers a Pharmacogenomics department, which is a growing segment in the personalized medicine market. The goal here is to tailor medications to the patient's genetic makeup. Fulgent Genetics' technology allows for the analysis of a patient's current genetic makeup and recommends medications based on that. Another important area of Fulgent Genetics is the direct-to-consumer sales of tests. This is particularly significant in the field of ancestry and genealogy research. Fulgent Genetics offers a variety of tests in this area and has already achieved great success. Overall, Fulgent Genetics offers a wide range of products and services mainly focused on the diagnosis of genetic diseases. However, the company also goes beyond that and provides solutions for a wide range of customers and applications. Fulgent Genetics is based in the US and has experienced rapid growth since its founding. The company's success is also reflected in the many awards it has received. It has been recognized multiple times and has established a reputation as one of the leading biotechnology companies in the world. Fulgent Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fulgent Genetics stock

FCF Conversion Rate (FCF/EBITDA) of Fulgent Genetics is 205.26 % in 2026.

Access this data via the Eulerpool API

Cash Flow — Fulgent Genetics

All Key Metrics — Fulgent Genetics